Retatrutide: How to Get It and How It Compares to Tirzepatide and Semaglutide

You saw the headline — a weight-loss drug that beat bariatric surgery numbers in a Phase 3 trial — and you typed the obvious next question into Google: how do you get retatrutide? Here is the blunt answer up front. You cannot buy it. It is not FDA approved, there is no pharmacy that legally fills it, and anyone selling you "retatrutide" today is selling an unapproved research peptide. The only place you receive the authentic Eli Lilly molecule under medical supervision is a clinical trial.

That said, the data behind the hype is real, and it is fresh. On May 21, 2026, Lilly reported the first pivotal Phase 3 results: up to 30.3% mean body-weight loss. This guide covers exactly what that trial showed, the three ways patients are actually accessing the drug right now and the risks of each, how retatrutide stacks up against tirzepatide and semaglutide, and the side effects that come with hitting three hormone receptors at once.

If you want a prescribing provider for an approved GLP-1 today while retatrutide finishes trials, we track weight-loss clinics in Houston, Miami, and Los Angeles with verified availability.

What retatrutide is and why it matters

Retatrutide (LY3437943) is an investigational molecule from Eli Lilly that activates three hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. The technical name is triple receptor agonist, or triagonist. Every GLP-1 drug on the market today activates one or two of those pathways. Retatrutide activates all three. That is the entire story behind why its numbers are higher.

The glucagon receptor is the difference-maker. Glucagon normally raises blood sugar, so stimulating it inside a weight-loss drug sounds backwards. But at the doses used in retatrutide, glucagon receptor activation mainly increases energy expenditure and accelerates fat oxidation in the liver. That is a separate lever from appetite suppression. So while semaglutide and tirzepatide turn down how much you want to eat, retatrutide does that and turns up how much energy you burn. Three biological pathways, attacked at the same time.

Most of the pharmacology here builds on what tirzepatide already does. If you want the groundwork, our tirzepatide dosing guide covers the dual-receptor mechanism and titration schedule that retatrutide extends with a third receptor.

Phase 3 TRIUMPH-1 results (2026)

On May 21, 2026, Lilly announced topline results from TRIUMPH-1 (NCT05929066), the first registrational Phase 3 obesity trial for retatrutide. All three doses met their primary and key secondary endpoints. The mean body-weight reductions at 80 weeks were:

• 4 mg: 47.2 lb (19.0%)
• 9 mg: 64.4 lb (25.9%)
• 12 mg: 70.3 lb (28.3%)

The number that broke records came from a subgroup: participants who started with a BMI of 35 or higher and stayed on the 12 mg dose through 104 weeks of total treatment lost an average of 85.0 lb — 30.3% of their starting body weight. For context, that approaches the average loss seen after sleeve gastrectomy, achieved with a once-weekly injection. Lilly reported the full results in its Phase 3 topline announcement.

Two things matter for timing. First, Lilly stated it plans to submit retatrutide to the FDA in 2026. Assuming a standard 10-to-12-month review, an approval decision could land in 2027 — not the 2028–2029 window many analysts predicted a year ago. Second, seven additional Phase 3 readouts from the broader TRIUMPH program are expected through 2026, including studies on cardiovascular outcomes and maintenance dosing. The picture is moving fast.

The earlier Phase 2 evidence

The Phase 3 results did not come out of nowhere. The Phase 2 trial published in the New England Journal of Medicine in 2023 (NCT04881110) enrolled 338 adults with obesity, or overweight with a weight-related condition. It tested 1, 3, 6, 8, and 12 mg weekly against placebo over 48 weeks.

At 48 weeks, the 12 mg group lost a mean of 24.2% of body weight, versus 2.1% on placebo. More striking: 26% of people on 12 mg lost more than 30% of their body weight — a threshold no randomized obesity trial had crossed before. The Phase 3 result of 28.3% at 80 weeks tells you the weight-loss curve kept climbing well past the point where semaglutide and tirzepatide flatten out.

How to get retatrutide right now

There are three pathways. Only one of them gives you the authentic, monitored molecule. Here they are in order of legitimacy.

1. Clinical trial enrollment — the only legitimate route

ClinicalTrials.gov lists the open TRIUMPH program sites. Eligible participants receive the drug, monitoring, and follow-up at no cost. Criteria vary by study arm but typically require a BMI of 30 or higher (or 27-plus with a weight-related condition), the absence of certain cardiac conditions, and a commitment to the full trial duration. Trials also exclude people who are pregnant or trying to conceive — if that applies to you, read our explainer on GLP-1 medications and fertility first. This is the only pathway where you receive clinical-grade retatrutide under a doctor's supervision.

2. Compounded retatrutide — legally murky and genuinely risky

Following the precedent set during the semaglutide and tirzepatide shortages, some pharmacies and telehealth sites began offering compounded retatrutide. The legal footing is shaky. Retatrutide is not FDA approved, so compounders are not operating under the shortage-based exemption that once applied to the approved drugs. The active ingredient may not be made under the sterility and purity standards of clinical-grade material, and there is no label, no verified concentration, and no recourse if something is wrong. We do not tell anyone what to take — but if you are weighing this, treat the absence of regulatory oversight as the headline fact, not the footnote.

3. Named-patient and international access

Some countries outside the US allow compassionate or named-patient access to investigational drugs. These programs are usually limited to patients who have documented failure of approved therapies and require institutional review. They are not a shortcut; they are a narrow, supervised exception.

If you are currently on tirzepatide and thinking about switching, understand the rebound dynamics first. Stopping a GLP-1 mid-treatment has predictable consequences — we cover them in weight regain after stopping GLP-1s. Any transition needs to be planned, not improvised.

How long until retatrutide works

Trial data showed meaningful weight loss starting around weeks 4 to 8. Appetite suppression came earlier — most people in the higher-dose groups reported reduced hunger inside the first two weeks. What sets retatrutide apart is the back half of the curve. Where semaglutide and tirzepatide typically start to plateau around weeks 36 to 48, retatrutide kept producing loss out to 80 weeks and beyond in the Phase 3 data.

Whether that reflects a genuinely higher ceiling or simply longer dosing is the kind of question only head-to-head trials settle. For the general pattern of what to expect month by month on any drug in this class, see our guide on how long GLP-1s take to work.

Retatrutide vs. tirzepatide

This is the comparison most people care about. On weight-loss magnitude, retatrutide now leads: 28.3% at 80 weeks in Phase 3 versus tirzepatide's 22.5% at 72 weeks in SURMOUNT-1. The extra glucagon receptor is doing real work. But magnitude is not the whole decision.

Tirzepatide is FDA approved, covered by some insurance, sold in known-purity formulations, and backed by years of Phase 3 and real-world safety data. Retatrutide has stronger efficacy signals and zero approved commercial availability. For almost everyone in 2026, tirzepatide is the rational choice unless you qualify for a TRIUMPH trial site. Our tirzepatide dosing guide walks through what real-world titration actually looks like, and we list tirzepatide providers in San Antonio and other metros with verified availability.

Retatrutide vs. semaglutide

Semaglutide (Wegovy) at 2.4 mg weekly produced 14.9% mean weight loss at 68 weeks in STEP-1. Retatrutide's 28.3% is roughly double that — but it is not an apples-to-apples comparison, because the trials used different durations, doses, and patient populations. The mechanistic gap is clean, though: semaglutide is a single GLP-1 receptor agonist that suppresses appetite and slows gastric emptying. Retatrutide does both of those and adds GIP and glucagon activation. More pathways means more weight-loss leverage — and more room for off-target effects that longer trials will continue to characterize.

Semaglutide also comes in more forms than retatrutide will at launch. If needles are your sticking point, see where the field is heading in our roundup of oral and sublingual GLP-1s. For finding a prescriber, we track semaglutide providers in Houston.

Side effects and the glucagon pathway

The core side-effect profile matches the GLP-1 class: nausea, diarrhea, vomiting, constipation, and decreased appetite, most prominent during dose escalation and easing once you settle at a stable dose. In the Phase 2 data, nausea ran 45–65% at the 12 mg dose. The full pattern in our GLP-1 side effects timeline applies to retatrutide, though the higher efficacy can mean somewhat more pronounced GI effects during titration.

The glucagon receptor adds two wrinkles you will not see with semaglutide or tirzepatide. A subset of patients in the highest-dose groups showed an elevated heart rate, a known glucagon-mediated effect, and diarrhea rates at 12 mg ran slightly higher than tirzepatide Phase 3 figures. Whether those differences hold at full Phase 3 scale is still being characterized across the TRIUMPH readouts.

Two cosmetic effects come with the territory of fast, deep weight loss regardless of which receptor the drug hits. The facial volume loss people call Ozempic face is more likely the more weight you drop, and retatrutide drops the most. The same goes for GLP-1 hair loss — telogen effluvium triggered by rapid weight loss, not by the molecule itself. Both are manageable, and both are worth understanding before you start.

What to tell your provider

Start the conversation with whether you qualify for a TRIUMPH trial site. ClinicalTrials.gov lets you search by zip code. Trial enrollment is the only pathway that gives you the authenticated molecule, real monitoring, and long-term safety follow-up — and the drug costs you nothing.

If you are considering compounded retatrutide from a telehealth provider, ask three specific questions: what is the source of the active ingredient, what sterility testing has been done, and under what regulatory framework is this being prescribed? If you cannot get clear answers, that silence is itself the answer. And if you take oral hormone therapy, raise it — GLP-1 drugs slow gastric emptying, which can change how oral medications absorb. We cover that interaction in GLP-1 medications and HRT.

Frequently asked questions

Can you buy retatrutide legally right now?

No. As of 2026, retatrutide is not approved by the FDA or any major regulator, so no pharmacy can legally fill a prescription for it. The only way to legally receive the authentic Eli Lilly molecule is by enrolling in a clinical trial, where the drug, monitoring, and follow-up are provided at no cost. Products marketed online as "retatrutide" are unapproved research peptides sold outside the regulatory system, with no verified purity, concentration, or sterility — and no legal recourse if something goes wrong.

How much weight do you lose on retatrutide?

In the Phase 3 TRIUMPH-1 trial reported in May 2026, participants lost an average of 28.3% of body weight (70.3 lb) on the 12 mg dose at 80 weeks. Those who started with a BMI of 35 or higher and continued on 12 mg through 104 weeks lost an average of 30.3% — about 85 pounds. The earlier Phase 2 trial showed 24.2% at 48 weeks. These are trial averages under medical supervision; individual results vary with dose, duration, starting weight, and how the drug is tolerated.

When will retatrutide be FDA approved?

Eli Lilly has said it plans to submit retatrutide to the FDA in 2026 following the positive TRIUMPH-1 readout. With a standard 10-to-12-month FDA review, an approval decision could realistically come in 2027 — earlier than the 2028–2029 timeline many analysts assumed a year ago. That timing depends on the full data package, the additional TRIUMPH Phase 3 readouts expected through 2026, and the FDA's review pace. Approval is never guaranteed until it is granted, so treat any specific date as a projection rather than a promise.

Is retatrutide better than tirzepatide (Mounjaro and Zepbound)?

On weight-loss magnitude, the trial numbers favor retatrutide: 28.3% at 80 weeks versus tirzepatide's 22.5% at 72 weeks in SURMOUNT-1. But these were separate trials, not a head-to-head comparison, so the gap is suggestive rather than definitive. Tirzepatide is FDA approved, available, often partially insured, and supported by years of safety data. Retatrutide is investigational with no commercial availability. For nearly everyone in 2026, tirzepatide is the practical choice unless you qualify for a retatrutide trial. "Better" depends on whether you weigh peak efficacy or access and proven safety more heavily.

Is compounded retatrutide safe?

There is no way to confirm that it is. Because retatrutide is not FDA approved, compounded versions fall outside the shortage-based exemption that once covered semaglutide and tirzepatide, leaving the practice on uncertain legal ground. The active ingredient may not be manufactured under clinical-grade sterility and purity standards, and there is no verified label, concentration, or quality oversight. If you are considering it, ask the provider about the ingredient source, sterility testing, and prescribing framework — and treat the absence of clear answers as meaningful. The supervised, verified option is a clinical trial.

How do you join a retatrutide clinical trial?

Search ClinicalTrials.gov for the TRIUMPH program by your zip code to find sites near you. Eligibility varies by study arm, but most require a BMI of 30 or higher (or 27-plus with a weight-related condition), no disqualifying cardiac conditions, and a willingness to commit to the full trial length, often 18 to 24 months. Trials generally exclude people who are pregnant or trying to conceive. Bring the specific trial identifier to your provider, who can help confirm whether you meet the criteria and coordinate a referral to a participating site.